Developing a Mouse Model for Marburg Virus
Author Information
Author(s): Kelly L Warfield, Derron A Alves, Steven B Bradfute, Daniel K Reed, Sean VanTongeren, Warren V Kalina, Gene G Olinger, Sina Bavari
Primary Institution: United States Army Medical Research Institute of Infectious Diseases
Hypothesis
Can we create a lethal mouse model for Marburg virus to aid in therapeutic testing?
Conclusion
The study successfully developed a mouse model for Marburg virus that significantly reduces the time to death, allowing for better evaluation of potential treatments.
Supporting Evidence
- Serial passaging of liver homogenates from MARV-infected scid mice reduced the time to death from 50-70 days to 7-10 days.
- The scid mouse-adapted MARV models showed similar properties to previously developed MARV models in guinea pigs and nonhuman primates.
- Candidate antiviral therapeutic molecules were evaluated using the scid mouse-adapted MARV models.
Takeaway
Researchers made a special mouse that gets sick from the Marburg virus much faster, which helps them test new medicines more quickly.
Methodology
The study involved serially passaging liver homogenates from Marburg-infected scid mice to create a lethal mouse-adapted virus.
Potential Biases
Potential bias in results due to the limited genetic diversity of the scid mouse model.
Limitations
The model may not fully replicate human responses to Marburg virus due to the use of scid mice.
Participant Demographics
BALB/c severe combined immunodeficient (scid) mice, aged 4 to 8 weeks.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website